CRISPR Therapeutics Stock News

PayPal remains a top fintech company in a massive industry that keeps growing. Palantir's business has turned a corner and is now profitable.

Cathie Wood has purchased a large stake in CRISPR Therapeutics for her ARK Invest ETFs. The company won a landmark regulatory approval this year, but analysts think the therapy may get off to a slow s

CRISPR Therapeutics just received its first product approval from regulators. Intellia Therapeutics is targeting a similar niche, and it has rich allies.

It's time for investors to ditch the search for the mythical crystal ball and instead embrace the algorithms when deciphering the best AI stock for your needs. As hyperbolic as it may sound, the futur

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. NASDAQ: VRTX announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for patients 12 years or older with recurrent vaso-occlusive

If you had to bet on two “big picture” sectors to invest in for the long haul, you can't go wrong with technology or healthcare. Both are omnipresent and, in their own ways, on the cutting edge of

CRISPR Therapeutics is becoming a big name in gene therapy. The industry is in its early growth stages, and the market could be massive in the future.

By and large, biotech businesses tend to carry significant risks for investors. They're usually at risk of running out of money or their medicines not working.

There are some good reasons why you should put your money to work right now instead of waiting. Your moves today could pay off over the long run.

The stock market has been responding to the recent approval of CRISPR Therapeutics' first drug. A successful commercial launch for Casgevy could make the biotech stock a top performer in 2024, but tha

CRISPR Therapeutics now has an approved gene therapy treatment in Casgevy. The treatment for sick cell disease received regulatory approval earlier this month.

CRISPR Therapeutics just reached a major milestone: approval of its first product. Pfizer is cheap and could deliver market-beating total returns thanks to its juicy dividend.

Phuong Khanh Morrow, chief medical officer at gene editing company Crispr Therapeutics (NASDAQ: CRSP ), resigned unexpectedly. The move comes a month after Crispr won Food and Drug Administration (FDA

CRISPR Therapeutics reached a major milestone when regulators approved its gene-editing treatment. The company's growth story is just getting started.

Crispr Therapeutics CRSP, +8.84% on Tuesday said that Phuong Khanh Morrow was resigning as the gene-editing company's chief medical officer, a move that takes hold on Jan. 26. The resignation was “n